A Study of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors (TREGCHECK 103)
2026年11月13日 更新者:Coherus Oncology, Inc.
A Phase 1/2, Multicenter, Open-Label, Multicohort Study Evaluating the Safety and Efficacy of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors
The primary purpose of this study is to evaluate the safety and tolerability of tagmokitug in combination with other therapies.
研究概览
研究类型
介入性
注册 (估计的)
12
阶段
- 阶段2
- 阶段1
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Clinical Operations Team
- 电话号码:+1-800-794-5434
- 邮箱:ClinicalTrials@coherus.com
学习地点
-
-
Washington
-
Seattle、Washington、美国、98109
- 招聘中
- Fred Hutchinson Cancer Center
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
男性
描述
Key Inclusion Criteria:
- Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.
- Resolved acute effects of any prior therapy to baseline severity or Grade 1 in accordance with National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0, except for adverse events (AEs) not constituting a safety risk per Investigator judgment.
mCRPC:
- Histologically confirmed adenocarcinoma of the prostate. Adenocarcinoma with focal small cell or neuroendocrine (NE) features based on immunohistochemistry (IHC) alone is permitted. However, small cell carcinoma, carcinoid tumor, mixed NE carcinoma, or large cell NE carcinoma is not permitted.
- Measurable Castration-resistant Prostate Cancer (mCRPC) as defined by PCWG3 criteria. Participant must have mCRPC that is metastatic either to bone, lymph node (LN), or both without clear evidence of either measurable or nonmeasurable metastasis to visceral organs at the time of screening scan.
- Participants must have been previously treated with at least 1 prior androgen-receptor pathway inhibitor (ARPI) (ie, abiraterone acetate, enzalutamide, apalutamide, darolutamide).
- Participants must have received at least one prior taxane therapy unless the participant is ineligible or refused. Participants must not have received other prior cytotoxic chemotherapy (ie, cisplatin, carboplatin, etoposide).
- Prior orchiectomy or medical castration. Participants who have not undergone orchiectomy, must be receiving ongoing androgen deprivation therapy (ADT) with a gonadotropin-releasing hormone (GnRH) analog with testosterone ≤50 nanogram per deciliter (ng/dL) prior to the first dose of study drug and must continue this therapy throughout the treatment phase.
Key Exclusion Criteria:
- History of prior malignancy other than the cancer under study that is progressing or has required active treatment within the past 3 years.
- Prior exposure to anti-CCR8 antibody agents.
- Prior allogeneic hematological stem cell transplantation or organ transplantation.
mCRPC:
- Any known prior history of brain metastases of prostate cancer (PCa).
- Treatment with antineoplastic therapy (including but not limited to cytotoxic chemotherapy, biologic agents, and investigational agents) other than ADT or ARPI within 28 days or <5× the elimination half-life (t½), whichever is earlier, before Day 1.
- Prior exposure to a T cell engager or human kallikrein 2 (KLK2) targeted therapy.
- Major surgery requiring general anesthesia within 28 days prior to the first dose of study treatment, still recovering from prior surgery, or with surgery scheduled during the study.
Additional protocol-defined inclusion and exclusion criteria apply.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:mCRPC: Tagmokitug + Pasritamig
|
Specified dose on specified days. Specified dose on specified days. |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
大体时间:Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
|
Number of Participants with Dose-limiting Toxicities (DLTs)
大体时间:Up to 56 Days
|
Up to 56 Days
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
客观缓解率 (ORR)
大体时间:最长约 2.5 年
|
最长约 2.5 年
|
|
缓解持续时间 (DOR)
大体时间:最长约 2.5 年
|
最长约 2.5 年
|
|
mCRPC: Prostate Specific Antigen >=50% Response Rate (PSA50) per Prostate Cancer Working Group 3 (PCWG3) Criteria
大体时间:Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
|
Disease Control Rate (DCR)
大体时间:Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
|
mCRPC: Radiographic Progression-free Survival (rPFS)
大体时间:Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
|
Progression-free Survival (rPFS)
大体时间:Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
|
Maximum Observed Serum Concentration of Tagmokitug (Cmax)
大体时间:Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
|
Concentration of Tagmokitug Immediately Before the Next Dose (Ctrough)
大体时间:Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
|
Number of Participants with Anti-drug Antibodies to Tagmokitug
大体时间:Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 研究主任:Study Director、Coherus Oncology
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (估计的)
2026年11月1日
初级完成 (估计的)
2028年8月1日
研究完成 (估计的)
2028年8月1日
研究注册日期
首次提交
2026年11月13日
首先提交符合 QC 标准的
2026年11月13日
首次发布 (实际的)
2026年11月18日
研究记录更新
最后更新发布 (实际的)
2026年11月18日
上次提交的符合 QC 标准的更新
2026年11月13日
最后验证
2026年11月1日
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- CHS-114-103
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
不
药物和器械信息、研究文件
研究美国 FDA 监管的药品
是的
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.